Cargando…

Testing the Effects of Disease‐Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial

Individuals with rheumatoid arthritis (RA) are at increased risk for atherosclerotic cardiovascular disease (ASCVD) events relative to the general population, potentially mediated by atherosclerotic plaques that are more inflamed and rupture prone. We sought to address whether RA immunomodulators re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giles, Jon T., Rist, Pamela M., Liao, Katherine P., Tawakol, Ahmed, Fayad, Zahi A., Mani, Venkatesh, Paynter, Nina P., Ridker, Paul M., Glynn, Robert J., Lu, Fengxin, Broderick, Rachel, Murray, Meredith, Vanni, Kathleen M. M., Solomon, Daniel H., Bathon, Joan M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207684/ https://www.ncbi.nlm.nih.gov/pubmed/33932148 http://dx.doi.org/10.1002/acr2.11256

Ejemplares similares

Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis
por: Solomon, Daniel H, et al.
Publicado: (2023)

Adverse Effects of Low‐Dose Methotrexate in a Randomized Double‐Blind Placebo‐Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial
por: Vanni, Kathleen M.M., et al.
Publicado: (2020)

Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis
por: Giles, Jon T, et al.
Publicado: (2005)

Left ventricular remodeling in rheumatoid arthritis patients without clinical heart failure
por: Park, Elizabeth, et al.
Publicado: (2023)

Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis
por: Nguyen, Thao H. P., et al.
Publicado: (2022)

Inflammation, Atherosclerosis, and Coronary Artery Disease: PET/CT for the Evaluation of Atherosclerosis and Inflammation
por: Alie, Nadia, et al.
Publicado: (2015)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
por: Judge, Andy, et al.
Publicado: (2017)

Respiratory symptoms and disease characteristics as predictors of pulmonary function abnormalities in patients with rheumatoid arthritis: an observational cohort study
por: Pappas, Dimitrios A, et al.
Publicado: (2010)

Association of Cross-Reactive Antibodies Targeting Peptidyl-Arginine Deiminase 3 and 4 with Rheumatoid Arthritis-Associated Interstitial Lung Disease
por: Giles, Jon T., et al.
Publicado: (2014)

Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs
por: Sokka, Tuulikki, et al.
Publicado: (2008)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response
por: Mikhaylenko, Dmitry S., et al.
Publicado: (2020)

Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment
por: Kerola, Anne Mirjam, et al.
Publicado: (2021)

Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis
por: Deyab, Gia, et al.
Publicado: (2021)

Do carotid MR surface coils affect PET quantification in PET/MR imaging?
por: Willemink, Martin J, et al.
Publicado: (2015)

Assessment of myocardial abnormalities in rheumatoid arthritis using a comprehensive cardiac magnetic resonance approach: a pilot study
por: Kobayashi, Yasuyuki, et al.
Publicado: (2010)

ECG non-specific ST-T and QTc abnormalities in patients with systemic lupus erythematosus compared with rheumatoid arthritis
por: Geraldino-Pardilla, Laura, et al.
Publicado: (2016)

Prospective changes in diastolic function in patients with rheumatoid arthritis
por: Park, Elizabeth, et al.
Publicado: (2022)

Utilization Patterns of Disease-Modifying Antirheumatic Drugs in Elderly Rheumatoid Arthritis Patients
por: Jin, Xue-Mei, et al.
Publicado: (2014)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
por: Xia, Yunfei, et al.
Publicado: (2016)

Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis
por: Bliddal, Sofie, et al.
Publicado: (2017)

Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors, Autoantibodies, and the Effect of Antirheumatic Therapies
por: Fazeli, Mir Sohail, et al.
Publicado: (2021)

The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
por: Hasegawa, Eriko, et al.
Publicado: (2023)

Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease‐Modifying Antirheumatic Drug Treatment
por: Sparks, Jeffrey A., et al.
Publicado: (2019)

New antirheumatic effects of biphosphonate treatment
por: Konenkova, L, et al.
Publicado: (2001)

Review of radiographic findings in COVID-19
por: Kaufman, Audrey E, et al.
Publicado: (2020)

Measuring Visceral Adipose Tissue Metabolic Activity in Sleep Apnea Utilizing Hybrid (18)F-FDG PET/MRI: A Pilot Study
por: Kundel, Vaishnavi, et al.
Publicado: (2021)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients
por: Joo, Young Bin, et al.
Publicado: (2022)

Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis: A Network Meta-Analysis
por: Guski, Louise S., et al.
Publicado: (2023)

The Cost-Effectiveness of and Adherence to Disease-Modifying Antirheumatic Drug (DMARD) Therapy in Rheumatoid Arthritis Patients in a Tertiary Care Teaching Hospital in Uttarakhand, India
por: Mittal, Gauri, et al.
Publicado: (2023)

Effects of Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Response to Periodontal Treatment in Patients with Rheumatoid Arthritis
por: Jung, Gyu-Un, et al.
Publicado: (2018)

Imaging Atherosclerosis
por: Tarkin, Jason M., et al.
Publicado: (2016)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
por: Smolen, Josef S, et al.
Publicado: (2014)

Feasibility of imaging superficial palmar arch using micro-ultrasound, 7T and 3T magnetic resonance imaging
por: Pruzan, Alison N, et al.
Publicado: (2017)

Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis
por: Giles, Jon T, et al.
Publicado: (2009)

Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia
por: Fletcher, Ashley, et al.
Publicado: (2022)

The effect of disease-modifying antirheumatic drugs on sleep and quality of life in older patients with rheumatoid arthritis
por: Azizli, Ali, et al.
Publicado: (2023)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
por: Cho, Soo-Kyung, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_daq3e3bcvi0ojktbcbtc4nb1jv